郑祖国，男，副研究员，硕士研究生导师。2018年毕业于中国药科大学生药学专业，获得博士学位。2018-2020年，于中国药科大学天然药物活性组分与药效国家重点实验室开展博士后研究工作。2020年破格晋升为副研究员。近5年来，发表论文15篇，以第一或共同第一作者身份在Autophagy (2篇), Cell Death and Differentiation, Theranostics, Biochemical Pharmacology, European Journal of Pharmacology (2篇), Journal of Pharmaceutical and Biomedical Analysis等国际知名学术期刊发表论文十余篇。申请发明专利11项，其中授权发明专利2项。主持国家自然科学基金青年项目，江苏省自然科学基金青年项目，博士后面上项目等纵向课题3项。

研究方向：
（1）利用现代分析及分子生物学等多学科手段建立高通量或高内涵药物筛选体系，致力于发现传统中药中抗代谢性疾病的活性成分（群）；（2）利用化学生物学等新技术探究中药活性成分的作用靶标，阐明其药效物质基础，并揭示其发挥药效的科学内涵。
近年来代表性科研成果：
1.Zu-Guo Zheng^#, Si-Tong Zhu^#, Hui-Min Cheng, Xin Zhang, Gang Cheng, Pyone Myat Thu, Supeng Perry Wang, Hui-Jun Li, Ming Ding, Lei Qiang, Xiao-Wei Chen, Qing Zhong, Ping Li* and Xiaojun Xu*. Discovery of a potent SCAP degrader that ameliorates HFD-induced obesity, hyperlipidemia, and insulin resistance via an autophagy-independent lysosomal pathway. Autophagy, 2020.1-22. (IF=11.1)
2.Zu-Guo Zheng^#, Hui-Min Cheng^#, Hui-Min Cheng, Ya-Ping Zhou, Si-Tong Zhu, Pyone Myat Thu, Hui-Jun Li, Ping Li* and Xiaojun Xu*. Dual targeting of SREBP2 and ERRα by carnosic acid suppresses RANKL-mediated osteoclastogenesis and prevents ovariectomy-induced bone loss. Cell Death & Differentiation, 2020: 1-18. (IF=10.7)
3.Zu-Guo Zheng^#, Xin Zhang, Xiao-Xiao Liu, Xiu-Xiu Jin, Lunzhi Dai, Hui-Min Cheng, Dan Jing, Pyone Myat Thu, Mu Zhang, Hongyang Li, Jing Zhu, Chang Liu, Bin Xue, Yu Li, Ligong Chen, Cheng Peng, Weiliang Zhu, Lin Wang, Junli Liu, Junli Liu*, Hui-Jun Li*, Ping Li* and Xiaojun Xu*. Inhibition of HSP90β Improves Lipid Disorders by Promoting Mature SREBPs Degradation via the Ubiquitin-proteasome System. Theranostics, 2019, 9(20): 5769-5783. (IF=8.6)
4.Pinghu Zhang^#*, Zuguo Zheng^#, Xiaohui Yang^#, Yuqian Zhang, Gendi Hu, Shuo Zhai, Dongping Wei. Discovery of novel 2-Aminonicotinonitrile Derivatives with new potential autophagy activity. Future medicinal Chemistry. 2020. Accepted. (IF=3.6)
5.Pyone Myat Thu^#, Zu-Guo Zheng^#, Ya-Ping Zhou, Yan-Yan Wang, Xin Zhang, Dan Jing, Hui-Min Cheng, Ji Li*, Ping Li* and Xiaojun Xu*. Phellodendrine chloride suppresses proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via micropinocytosis. European Journal of Pharmacology. 2019, 805: 23-34. (IF: 3.3, co-first author)
6.Pinghu Zhang^#*,Zuguo Zheng^#, Li Ling^#, Xiaohui Yang^#, Ni Zhang, Xue Wang, Maozhi Hu, Yu Xia, Yiwen Ma, Haoran Yang, Yunyi Wang and Hongqi Liu. w09, a novel autophagy enhancer, induces autophagy-dependent cell apoptosis via activation of the EGFR-mediated RAS-RAF1-MAP2K-MAPK1/3 pathway. Autophagy. 2017, 13;7:1093-1112. (IF: 11.1，co-first author)
7.Zu-Guo Zheng^#, Xin Zhang, Ya-Ping Zhou, Chong Lu, Pyone Myat Thu, Cheng Qian, Mu Zhang, Ping Li, Hui-Jun Li* and Xiaojun Xu*. Anhydroicaritin, a SREBPs inhibitor, inhibits RANKL-induced osteoclastic differentiation and improves diabetic osteoporosis in STZ-induced mice. European Journal of Pharmacology. 2017,15;809:156-162. (IF: 3.3)
8.Zu-Guo Zheng^#, Ya-Ping Zhou^#, Xin Zhang, Pyone Myat Thu, Zhi-Shen Xie, Chong Lu, Tao Pang, Bin Xue, Da-Qian Xu, Yan Chen, Xiao-Wei Chen, Hui-Jun Li* and Xiaojun Xu*. Anhydroicaritin improves diet-induced obesity and hyperlipidemia and alleviates insulin resistance by suppressing SREBPs activation. Biochemical Pharmacology. 2016, 15;122:42-61. (IF: 5.09)
授权发明专利：
1. 张评浒; 杨晓慧; 郑祖国; 张陆勇, 诱发自噬的2-氨基烟腈类化合物及其用途, 2016.10.05-2034.05.30, 中国, ZL1.5. (授权)
2. 徐晓军; 李会军; 卢翀; 郑祖国; 李萍, 白花前胡乙素的医药用途, 2017.01.22, 中国, CN8.2. （授权）
联系方式：
通讯地址：江苏省南京市鼓楼区童家巷24号新大楼七楼
邮政编码：210009
联系电话：**
电子邮箱：zuguozheng@cpu.edu.cn; zhengzuguo@foxmail.com